Everence Capital Management Inc. Sells 1,030 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Everence Capital Management Inc. lessened its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 39,650 shares of the biopharmaceutical company’s stock after selling 1,030 shares during the period. Everence Capital Management Inc.’s holdings in Gilead Sciences were worth $3,212,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. PCA Investment Advisory Services Inc. bought a new position in Gilead Sciences during the 2nd quarter worth $25,000. OFI Invest Asset Management acquired a new stake in shares of Gilead Sciences during the 3rd quarter worth $26,000. Tompkins Financial Corp grew its holdings in shares of Gilead Sciences by 223.1% during the 3rd quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 241 shares in the last quarter. Fortitude Family Office LLC acquired a new stake in shares of Gilead Sciences during the 4th quarter worth $29,000. Finally, Sanctuary Wealth Management L.L.C. acquired a new stake in shares of Gilead Sciences during the 4th quarter worth $33,000. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Trading Down 0.6 %

GILD stock traded down $0.44 during mid-day trading on Tuesday, reaching $67.31. The company’s stock had a trading volume of 4,971,311 shares, compared to its average volume of 7,347,464. The company has a market cap of $83.81 billion, a price-to-earnings ratio of 15.06, a price-to-earnings-growth ratio of 0.86 and a beta of 0.19. The business’s 50 day moving average price is $72.61 and its 200 day moving average price is $76.78. The company has a current ratio of 1.43, a quick ratio of 1.27 and a debt-to-equity ratio of 1.08. Gilead Sciences, Inc. has a 12 month low of $67.18 and a 12 month high of $87.86.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share for the quarter, missing analysts’ consensus estimates of $1.76 by ($0.04). The business had revenue of $7.12 billion during the quarter, compared to the consensus estimate of $7.10 billion. Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The company’s revenue for the quarter was down 3.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.67 earnings per share. On average, equities research analysts predict that Gilead Sciences, Inc. will post 7.08 EPS for the current year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 28th. Shareholders of record on Friday, March 15th were issued a $0.77 dividend. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.75. This represents a $3.08 dividend on an annualized basis and a yield of 4.58%. The ex-dividend date of this dividend was Thursday, March 14th. Gilead Sciences’s payout ratio is presently 68.44%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $72.96, for a total value of $145,920.00. Following the completion of the sale, the insider now owns 96,304 shares of the company’s stock, valued at $7,026,339.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.29% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently issued reports on GILD shares. Mizuho reduced their target price on Gilead Sciences from $101.00 to $90.00 and set a “buy” rating on the stock in a report on Thursday, February 22nd. Truist Financial lowered Gilead Sciences from a “buy” rating to a “hold” rating and reduced their price objective for the company from $91.00 to $82.00 in a research note on Thursday, February 22nd. Wells Fargo & Company reduced their price objective on Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating on the stock in a research note on Monday, March 4th. Cantor Fitzgerald reduced their price objective on Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 7th. Finally, Oppenheimer reduced their price objective on Gilead Sciences from $115.00 to $105.00 and set an “outperform” rating on the stock in a research note on Monday, February 12th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Gilead Sciences has a consensus rating of “Hold” and a consensus price target of $85.36.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.